Details

Autor(en) / Beteiligte

• Maruyama, Hiroki
• Miyata, Kaori
• Mikame, Mariko
• Taguchi, Atsumi
• Guili, Chu
• Shimura, Masaru
• Murayama, Kei
• Inoue, Takeshi
• Yamamoto, Saori
• Sugimura, Koichiro
• Tamita, Koichi
• Kawasaki, Toshihiro
• Kajihara, Jun
• Onishi, Akifumi
• Sugiyama, Hitoshi
• Sakai, Teiko
• Murata, Ichijiro
• Oda, Takamasa
• Toyoda, Shigeru
• Hanawa, Kenichiro
• Fujimura, Takeo
• Ura, Shigehisa
• Matsumura, Mimiko
• Takano, Hideki
• Yamashita, Satoshi
• Matsukura, Gaku
• Tazawa, Ryushi
• Shiga, Tsuyoshi
• Ebato, Mio
• Satoh, Hiroshi
• Ishii, Satoshi

Titel

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis

Ist Teil von

• Genetics in medicine, 2019-02, Vol.21 (2), p.512-515

Ort / Verlag

New York: Nature Publishing Group US

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows: